BRIEF-AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint By: Reuters: Company News August 15, 2016 at 07:10 AM EDT * Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events Read More >> Related Stocks: Acelrx Pharmaceutica